A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

Study Summary

This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose levels. Participants who have completed the first 28 weeks may participate in an exploratory extension study.

Conditions

Obesity Overweight or Obesity

Interventions / Drugs

MET097 Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment225 participants

Primary Completion—

Lead SponsorMetsera, a wholly owned subsidiary of Pfizer

Data Retrieved2026-04-11 02:55:53.189808+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.